JP Morgan Maintains Overweight on Ultragenyx Pharmaceutical, Raises Price Target to $80

Benzinga Newsdesk www.benzinga.com Positive 75.6%

Neg 0% Neu 0% Pos 75.6%

JP Morgan analyst Anupam Rama maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Overweight and raises the price target from $75 to $80.